一致B(200028) - 2020 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2020 was ¥12,824,196,278.66, representing a 6.23% increase compared to ¥11,879,309,078.82 in the same period last year[8]. - Net profit attributable to shareholders decreased by 16.91% to ¥248,800,655.88 from ¥300,149,012.08 in the previous year[9]. - The basic earnings per share fell by 17.14% to ¥0.58, down from ¥0.70 in the same period last year[8]. - Net profit for the period was ¥295,088,278.12, a decrease of 14.4% from ¥344,780,874.38 in the same period last year[66]. - The company's total revenue for the current period is approximately ¥883.09 million, a decrease of 9.9% compared to ¥980.47 million in the previous period[70]. - Operating profit for the current period is approximately ¥75.61 million, down 31.1% from ¥109.79 million in the previous period[73]. - Net profit for the current period is approximately ¥71.99 million, a decrease of 30.8% compared to ¥104.31 million in the previous period[73]. - Basic and diluted earnings per share for the current period are both ¥0.58, down from ¥0.70 in the previous period[69]. Cash Flow - The net cash flow from operating activities improved by 12.70%, reaching -¥688,273,848.63 compared to -¥759,367,352.29 in the previous year[8]. - Cash received from operating activities increased by 295.95 million yuan, a growth rate of 215.29%, mainly due to emergency reserve funds received for COVID-19 prevention[29]. - Cash flow from operating activities for the current period is approximately -¥688.27 million, an improvement from -¥788.38 million in the previous period[80]. - Cash inflow from operating activities totals approximately ¥13.64 billion, compared to ¥11.58 billion in the previous period, indicating a growth of 17.8%[80]. - Cash outflow for purchasing goods and services is approximately ¥12.83 billion, an increase from ¥11.08 billion in the previous period[80]. - The net cash flow from operating activities was -197,632,987.50 RMB, compared to 37,832,801.44 RMB in the previous period[84]. - Cash inflow from operating activities totaled 1,085,255,063.29 RMB, an increase from 988,076,866.51 RMB year-over-year[84]. - Cash outflow from operating activities was 1,282,888,050.79 RMB, up from 950,244,065.07 RMB in the previous period[84]. Assets and Liabilities - Total assets increased by 8.38% to ¥36,882,640,680.62 from ¥30,855,284,546.74 at the end of the previous year[8]. - Total liabilities reached ¥21.10 billion, up from ¥18.46 billion, which is an increase of about 14.0%[50]. - The company's total assets increased to ¥13,688,604,415.91, compared to ¥13,523,975,229.47 in the previous period, marking a growth of 1.2%[60]. - Total liabilities rose to ¥3,509,982,947.13, compared to ¥3,417,348,556.50, indicating an increase of 2.7%[60]. - The company's cash and cash equivalents decreased to ¥7.34 billion from ¥8.89 billion, a decline of approximately 17.4%[44]. - Current assets totaled ¥28.54 billion, up from ¥26.90 billion, indicating a growth of about 6.1%[52]. - Non-current assets totaled ¥8.34 billion, an increase from ¥7.13 billion, reflecting a growth of about 16.9%[52]. - Total cash and cash equivalents at the end of the period were 2,804,030,292.66 RMB, up from 1,610,546,696.63 RMB in the previous period[86]. Investments and Acquisitions - The company acquired a 75% stake in Shanghai Pudong New Area Pharmaceutical Materials Co., Ltd., impacting the consolidated financial statements for Q1 2020[8]. - Cash flow from investing activities decreased by 707.32 million yuan, a decline of 1,655.61%, mainly due to cash payments for the acquisition of Shanghai Dingqun Enterprise Management Consulting Co., Ltd.[29]. - The company reported an investment cash outflow of approximately ¥767.80 million, compared to ¥232.10 million in the previous period, indicating increased investment activity[80]. - The company received approximately ¥22.11 million in cash from investment activities, down from ¥189.63 million in the previous period[80]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 26,399, with the largest shareholder, China National Pharmaceutical Group, holding 56.06%[16]. - The company's equity attributable to shareholders increased to ¥13.06 billion from ¥12.91 billion, a rise of approximately 1.2%[53]. Operational Changes - Accounts receivable decreased by 264.66 million yuan, a decline of 33.59%, mainly due to changes in procurement models of hospital clients influenced by GPO policies[26]. - Prepayments increased by 387.32 million yuan, a growth rate of 99.36%, primarily due to emergency reserve material payments related to COVID-19 prevention[26]. - Intangible assets increased by 260.25 million yuan, a growth rate of 69.37%, mainly due to the acquisition of Shanghai Dingqun Enterprise Management Consulting Co., Ltd. by subsidiary Guoda Pharmacy[26]. - Goodwill increased by 503.12 million yuan, a growth rate of 49.81%, resulting from the acquisition of Shanghai Dingqun Enterprise Management Consulting Co., Ltd.[26]. - Short-term borrowings increased by 1.33 billion yuan, a growth rate of 91.69%, due to increased supply chain financing and special loans for COVID-19 prevention[26]. - Financial expenses increased by 13.41 million yuan, a growth rate of 85.97%, mainly due to the impact of new leasing standards[26]. - Other income increased by 12.04 million yuan, a growth rate of 1,105.17%, primarily due to increased tax reductions and various special subsidies[29]. - The company reported a decrease in employee compensation payable to ¥191 million from ¥260 million, a decline of approximately 26.4%[50]. Future Outlook - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[63].